DGIdb - TOPIRAMATE Drug Record

TOPIRAMATE chembl:CHEMBL220492 Approved

Alternate Names:

RWJ-17021-000
MCN-4853
QUDEXY XR
TROKENDI XR
USL255
RWJ-17021
EPITOMAX
TOPAMAX
USL-255
TOPAMAX SPRINKLE
TOPIRAMATE
2,3:4,5-DI-O-ISOPROPYLIDENE-BETA-D-FRUCTOPYRANOSE SULFAMATE
TPM
TOPAMAX®
TIPIRAMATE
[(1R,2S,6S,9R)-4,4,11,11-TETRAMETHYL-3,5,7,10,12-PENTAOXATRICYCLO[7.3.0.0^{2,6}]DODECAN-6-YL]METHYL SULFAMATE
TIPIRAMATO
2,3:4,5-BIS-O-(1-METHYLETHYLIDENE)-BETA-D-FRUCTOPYRANOSE SULFAMATE
TOPOMAX
TOPIRAMATUM
TOPIRAMATO
chemidplus:97240-79-4
drugbank:00273
pubchem.compound:5284627
rxcui:38404
chembl:CHEMBL220492

Drug Info:

Drug Categories	therapeutic uses
Drug Categories	specialty uses of chemicals
Drug Categories	protective agents
Drug Categories	physiological effects of drugs
Drug Categories	pharmacologic actions
Drug Categories	neuroprotective agents
Drug Categories	nervous system
Drug Categories	monosaccharides
Drug Categories	ketoses
Drug Categories	hexoses
Drug Categories	cytochrome p-450 cyp3a4 inducers (weak)
Drug Categories	cytochrome p-450 cyp3a inducers
Drug Categories	cytochrome p-450 cyp2c19 inhibitors (moderate)
Drug Categories	cytochrome p-450 cyp2c19 inhibitors
Drug Categories	chemical actions and uses
Drug Categories	central nervous system depressants
Drug Categories	central nervous system agents
Drug Categories	carbohydrates
Drug Categories	anticonvulsants
Drug Categories	anti-obesity agents
Drug Groups	approved
Drug Type	small molecule
Drug Class	anticonvulsants
Drug Class	anti-migraine agents
Year of Approval	1996
FDA Approval	1996
Drug Indications	anti-migraine agents
Drug Indications	Anticonvulsants
Drug Indications	anticonvulsant,antimigraine agent
FDA Approval	approved
Drug Class	small molecule
Drug Indications	anticonvulsant
Drug Categories	p-glycoprotein substrates
Drug Categories	miscellaneous anticonvulsants
Drug Categories	fructose
Drug Categories	enzyme inducing antiepileptic drugs
Drug Categories	drugs that are mainly renally excreted
Drug Categories	decreased central nervous system disorganized electrical activity
Drug Categories	cytochrome p-450 substrates
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	cytochrome p-450 enzyme inducers
Drug Categories	cytochrome p-450 cyp3a4 inducers (strength unknown)
Drug Categories	cytochrome p-450 cyp3a4 inducers
Drug Categories	cytochrome p-450 cyp2c19 inhibitors (strength unknown)

(5 More Sources)

Publications:

Ceulemans et al., 2004, "Severe myoclonic epilepsy in infancy". Relevance for the clinician of severe epilepsy starting in infancy., Acta Neurol Belg
Nieto Barrera et al., [Severe myoclonic epilepsy in infancy (Dravet's syndrome). Its nosological characteristics and therapeutic aspects]., Rev Neurol
Coppola et al., 2002, Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial., Epilepsy Res.
Ceulemans et al., 2004, Severe myoclonic epilepsy in infancy: toward an optimal treatment., J. Child Neurol.
Korff et al., 2007, Dravet syndrome (severe myoclonic epilepsy in infancy): a retrospective study of 16 patients., J. Child Neurol.
Braga et al., 2009, Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons., J. Pharmacol. Exp. Ther.
Nowakowska et al., 2009, Memory improving and antidepressant effects of topiramate in rats., Arzneimittelforschung
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Chung JY et al., 2014, Efficacy of zonisamide in migraineurs with nonresponse to topiramate., Biomed Res Int
Garnett WR, 2000, Clinical pharmacology of topiramate: a review., Epilepsia
Ray LA et al., 2009, A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers., Exp Clin Psychopharmacol
Gryder et al., 2003, Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons., J. Neurosci.
Kaminski et al., 2004, Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist., Neuropharmacology
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Rogawski et al., 2003, GluR5 kainate receptors, seizures, and the amygdala., Ann. N. Y. Acad. Sci.
Dodgson et al., 2000, Topiramate as an inhibitor of carbonic anhydrase isoenzymes., Epilepsia
Masereel et al., 2002, Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties., J. Med. Chem.
Vullo et al., 2004, Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides., J. Med. Chem.
Abbate et al., 2004, Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX., Bioorg. Med. Chem. Lett.
Yang B et al., 2008, Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides., Bioorg Med Chem
Mirza NS et al., 2011, Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors., Pharmacogenet Genomics
Ma CL et al., 2014, Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy., Pharmacogenomics
Kwan P et al., 2008, Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression., Pharmacogenet Genomics
Maryanoff et al., 2005, Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform., J. Med. Chem.
Winum et al., 2005, Sulfamates and their therapeutic potential., Med Res Rev
Di Fiore et al., 2007, Carbonic anhydrase inhibitors: binding of an antiglaucoma glycosyl-sulfanilamide derivative to human isoform II and its consequences for the drug design of enzyme inhibitors incorporating sugar moieties., Bioorg. Med. Chem. Lett.
Ma et al., 2007, Topiramate reduced sweat secretion and aquaporin-5 expression in sweat glands of mice., Life Sci.
Casini et al., 2003, Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV., Bioorg. Med. Chem. Lett.
Li QS et al., 2016, A candidate-gene association study of topiramate-induced weight loss in obese patients with and without type 2 diabetes mellitus., Pharmacogenet Genomics
Nishimori I et al., 2007, Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides., Bioorg Med Chem
Maryanoff BE, 2016, Phenotypic Assessment and the Discovery of Topiramate., ACS Med Chem Lett
Kuzmiski JB et al., 2005, Topiramate inhibits the initiation of plateau potentials in CA1 neurons by depressing R-type calcium channels., Epilepsia
Wormuth C et al., 2016, Review: Ca<sub>v</sub>2.3 R-type Voltage-Gated Ca<sup>2+</sup> Channels - Functional Implications in Convulsive and Non-convulsive Seizure Activity., Open Neurol J
Lehmann WD et al., 1976, [Frequency of obstetrical operations and perinatal mortality before and after admission of continuous fetal monitoring (author's transl)]., Geburtshilfe Frauenheilkd
Mula M et al., 2006, Psychopharmacology of topiramate: from epilepsy to bipolar disorder., Neuropsychiatr Dis Treat

TOPIRAMATE CA4

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Publications:

Dodgson et al., 2000, Topiramate as an inhibitor of carbonic anhydrase isoenzymes., Epilepsia

Masereel et al., 2002, Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties., J. Med. Chem.

Vullo et al., 2004, Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides., J. Med. Chem.

TOPIRAMATE CA12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Publications:

Mirza NS et al., 2011, Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors., Pharmacogenet Genomics

TOPIRAMATE CA2

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name topiramate controlled release,Trokesa

Novel drug target Established target

Trial Name topiramate tablet,Topamax

Publications:

Maryanoff et al., 2005, Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform., J. Med. Chem.

Winum et al., 2005, Sulfamates and their therapeutic potential., Med Res Rev

Di Fiore et al., 2007, Carbonic anhydrase inhibitors: binding of an antiglaucoma glycosyl-sulfanilamide derivative to human isoform II and its consequences for the drug design of enzyme inhibitors incorporating sugar moieties., Bioorg. Med. Chem. Lett.

TOPIRAMATE GRIK2

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Glutamate receptor ionotropic kainate antagonist

Publications:
TOPIRAMATE SCN4A

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

Publications:
TOPIRAMATE GRIA3

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Glutamate receptor ionotropic AMPA antagonist

Direct Interaction yes

Publications:
TOPIRAMATE GRIK4

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Glutamate receptor ionotropic kainate antagonist

Publications:
TOPIRAMATE SCN10A

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

Publications:
TOPIRAMATE GRIA2

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Glutamate receptor ionotropic AMPA antagonist

Direct Interaction yes

Publications:
TOPIRAMATE SCN5A

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

Publications:
TOPIRAMATE SCN3A

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

Publications:
TOPIRAMATE SCN7A

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

Publications:
TOPIRAMATE GRIK3

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Glutamate receptor ionotropic kainate antagonist

Direct Interaction yes

Publications:
TOPIRAMATE GRIA4

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Glutamate receptor ionotropic AMPA antagonist

Direct Interaction yes

Publications:
TOPIRAMATE SCN11A

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

Publications:
TOPIRAMATE CA7

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Publications:
TOPIRAMATE GRIA1

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Glutamate receptor ionotropic AMPA antagonist

Direct Interaction yes

Publications:
TOPIRAMATE SCN8A

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

Publications:
TOPIRAMATE SCN9A

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

Publications:

TOPIRAMATE SCN1A

Interaction Types & Directionality:

inhibitor (inhibitory)

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

Trial Name topiramate controlled release,Trokesa

Publications:

Ceulemans et al., 2004, "Severe myoclonic epilepsy in infancy". Relevance for the clinician of severe epilepsy starting in infancy., Acta Neurol Belg

Nieto Barrera et al., [Severe myoclonic epilepsy in infancy (Dravet's syndrome). Its nosological characteristics and therapeutic aspects]., Rev Neurol

Coppola et al., 2002, Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial., Epilepsy Res.

TOPIRAMATE GABRA1

Interaction Types & Directionality:

agonist (activating)

positive modulator (activating)

Interaction Info:

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Direct Interaction yes

Trial Name topiramate controlled release,Trokesa

Publications:

Braga et al., 2009, Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons., J. Pharmacol. Exp. Ther.

Nowakowska et al., 2009, Memory improving and antidepressant effects of topiramate in rats., Arzneimittelforschung

Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov

TOPIRAMATE GRIK1

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name topiramate controlled release,Trokesa

Novel drug target Established target

Trial Name topiramate tablet,Topamax

Publications:

Ray LA et al., 2009, A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers., Exp Clin Psychopharmacol

Braga et al., 2009, Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons., J. Pharmacol. Exp. Ther.

Gryder et al., 2003, Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons., J. Neurosci.

TOPIRAMATE SCN2A

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

Publications:

Ma CL et al., 2014, Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy., Pharmacogenomics

Kwan P et al., 2008, Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression., Pharmacogenet Genomics

TOPIRAMATE CA1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Publications:

Dodgson et al., 2000, Topiramate as an inhibitor of carbonic anhydrase isoenzymes., Epilepsia

Nishimori I et al., 2007, Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides., Bioorg Med Chem

TOPIRAMATE CACNA1E

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:

Maryanoff BE, 2016, Phenotypic Assessment and the Discovery of Topiramate., ACS Med Chem Lett

Kuzmiski JB et al., 2005, Topiramate inhibits the initiation of plateau potentials in CA1 neurons by depressing R-type calcium channels., Epilepsia

Wormuth C et al., 2016, Review: Cav2.3 R-type Voltage-Gated Ca2+ Channels - Functional Implications in Convulsive and Non-convulsive Seizure Activity., Open Neurol J

TOPIRAMATE CA3

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Dodgson et al., 2000, Topiramate as an inhibitor of carbonic anhydrase isoenzymes., Epilepsia

Nishimori I et al., 2007, Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides., Bioorg Med Chem

Lehmann WD et al., 1976, [Frequency of obstetrical operations and perinatal mortality before and after admission of continuous fetal monitoring (author's transl)]., Geburtshilfe Frauenheilkd

TOPIRAMATE CACNA1C

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:

Mula M et al., 2006, Psychopharmacology of topiramate: from epilepsy to bipolar disorder., Neuropsychiatr Dis Treat
TOPIRAMATE GABRA5

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Direct Interaction yes

Publications:
TOPIRAMATE GABRG3

Interaction Types & Directionality:

n/a

Interaction Info:

Direct Interaction yes

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Publications:
TOPIRAMATE GABRD

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Direct Interaction yes

Publications:
TOPIRAMATE GABRA2

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Direct Interaction yes

Publications:
TOPIRAMATE GABRE

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Direct Interaction yes

Publications:
TOPIRAMATE GABRA3

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Direct Interaction yes

Publications:
TOPIRAMATE GABRG2

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Direct Interaction yes

Publications:
TOPIRAMATE GABRQ

Interaction Types & Directionality:

n/a

Interaction Info:

Direct Interaction yes

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Publications:
TOPIRAMATE GABRA4

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Direct Interaction yes

Publications:
TOPIRAMATE GABRB3

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Direct Interaction yes

Publications:
TOPIRAMATE GABRB1

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Direct Interaction yes

Publications:
TOPIRAMATE GABRP

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Direct Interaction yes

Publications:
TOPIRAMATE GABRG1

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Direct Interaction yes

Publications:
TOPIRAMATE GABRB2

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Direct Interaction yes

Publications:
TOPIRAMATE GABRA6

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Direct Interaction yes

Publications:
TOPIRAMATE AQP4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Yang B et al., 2008, Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides., Bioorg Med Chem
TOPIRAMATE INSR

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Li QS et al., 2016, A candidate-gene association study of topiramate-induced weight loss in obese patients with and without type 2 diabetes mellitus., Pharmacogenet Genomics
TOPIRAMATE CYP2C19

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
TOPIRAMATE NR1I2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

DrugBank: DB00273

Version: 5.1.7

Alternate Names:

TOPIRAMATE DrugBank Drug Name

97240-79-4 CAS Number

Abbott-topiramate Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories anti-obesity agents

Publications:

Nishimori I et al., 2007, Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides., Bioorg Med Chem

Dodgson et al., 2000, Topiramate as an inhibitor of carbonic anhydrase isoenzymes., Epilepsia

Wormuth C et al., 2016, Review: Cav2.3 R-type Voltage-Gated Ca2+ Channels - Functional Implications in Convulsive and Non-convulsive Seizure Activity., Open Neurol J

TEND: TOPIRAMATE
- Version: 01-August-2011
Alternate Names:

TOPIRAMATE Primary Drug Name

Drug Info:

Year of Approval 1996

Drug Class anti-migraine agents

Drug Class anticonvulsants

Publications:
TdgClinicalTrial: TOPIRAMATE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications anticonvulsant

Drug Class small molecule

FDA Approval approved

Publications:
DTC: TOPIRAMATE
- Version: 02-September-2020
Alternate Names:

CHEMBL220492 ChEMBL Drug ID

Drug Info:

Publications:

Yang B et al., 2008, Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides., Bioorg Med Chem

PharmGKB: topiramate

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Ray LA et al., 2009, A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers., Exp Clin Psychopharmacol

Kwan P et al., 2008, Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression., Pharmacogenet Genomics

Ma CL et al., 2014, Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy., Pharmacogenomics

GuideToPharmacologyInteractions: 178103455
- Version: 20-July-2020
Alternate Names:

TOPIRAMATE GuideToPharmacology Ligand Name

Drug Info:

Publications:
TTD: Topiramate
- Version: 2020.06.01
Alternate Names:

D07VDZ TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL220492
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL220492
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False
Direct Interaction?	False

Trial Name	topiramate controlled release,Trokesa
Novel drug target	Established target
Trial Name	topiramate tablet,Topamax

Direct Interaction	yes
Mechanism of Interaction	Glutamate receptor ionotropic kainate antagonist

Direct Interaction	yes
Mechanism of Interaction	Sodium channel alpha subunit blocker

Mechanism of Interaction	Glutamate receptor ionotropic AMPA antagonist
Direct Interaction	yes

Mechanism of Interaction	GABA-A receptor; anion channel positive modulator
Direct Interaction	yes
Trial Name	topiramate controlled release,Trokesa

TOPIRAMATE	DrugBank Drug Name
97240-79-4	CAS Number
Abbott-topiramate	Drug Brand

TOPIRAMATE Drug Record

TOPIRAMATE chembl:CHEMBL220492 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

Publications: Mirza NS et al., 2011, Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors., Pharmacogenet Genomics

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name topiramate controlled release,Trokesa Novel drug target Established target Trial Name topiramate tablet,Topamax

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Glutamate receptor ionotropic kainate antagonist

Publications:

Interaction Types & Directionality: blocker (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Sodium channel alpha subunit blocker

Publications:

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Mechanism of Interaction Glutamate receptor ionotropic AMPA antagonist Direct Interaction yes

Publications:

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Glutamate receptor ionotropic kainate antagonist

Publications:

Interaction Types & Directionality: blocker (inhibitory)

Interaction Info: Mechanism of Interaction Sodium channel alpha subunit blocker Direct Interaction yes

Publications:

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Mechanism of Interaction Glutamate receptor ionotropic AMPA antagonist Direct Interaction yes

Publications:

Interaction Types & Directionality: blocker (inhibitory)

Interaction Info: Mechanism of Interaction Sodium channel alpha subunit blocker Direct Interaction yes

Publications:

Interaction Types & Directionality: blocker (inhibitory)

Interaction Info: Mechanism of Interaction Sodium channel alpha subunit blocker Direct Interaction yes

Publications:

Interaction Types & Directionality: blocker (inhibitory)

Interaction Info: Mechanism of Interaction Sodium channel alpha subunit blocker Direct Interaction yes

Publications:

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Mechanism of Interaction Glutamate receptor ionotropic kainate antagonist Direct Interaction yes

Publications:

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Mechanism of Interaction Glutamate receptor ionotropic AMPA antagonist Direct Interaction yes

Publications:

Interaction Types & Directionality: blocker (inhibitory)

Interaction Info: Mechanism of Interaction Sodium channel alpha subunit blocker Direct Interaction yes

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

Publications:

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Mechanism of Interaction Glutamate receptor ionotropic AMPA antagonist Direct Interaction yes

Publications:

Interaction Types & Directionality: blocker (inhibitory)

Interaction Info: Mechanism of Interaction Sodium channel alpha subunit blocker Direct Interaction yes

Publications:

Interaction Types & Directionality: blocker (inhibitory)

Interaction Info: Mechanism of Interaction Sodium channel alpha subunit blocker Direct Interaction yes

Publications:

Interaction Types & Directionality: inhibitor (inhibitory) blocker (inhibitory)

Interaction Info: Mechanism of Interaction Sodium channel alpha subunit blocker Direct Interaction yes Trial Name topiramate controlled release,Trokesa

Interaction Types & Directionality: agonist (activating) positive modulator (activating)

Interaction Info: Mechanism of Interaction GABA-A receptor; anion channel positive modulator Direct Interaction yes Trial Name topiramate controlled release,Trokesa

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name topiramate controlled release,Trokesa Novel drug target Established target Trial Name topiramate tablet,Topamax

Interaction Types & Directionality: blocker (inhibitory)

Interaction Info: Mechanism of Interaction Sodium channel alpha subunit blocker Direct Interaction yes

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? False Specific Action of the Ligand Inhibition Endogenous Drug? False

Publications: Dodgson et al., 2000, Topiramate as an inhibitor of carbonic anhydrase isoenzymes., Epilepsia Nishimori I et al., 2007, Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides., Bioorg Med Chem

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

Publications: Mula M et al., 2006, Psychopharmacology of topiramate: from epilepsy to bipolar disorder., Neuropsychiatr Dis Treat

Interaction Types & Directionality: n/a

Interaction Info: Mechanism of Interaction GABA-A receptor; anion channel positive modulator Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Publications:

Mirza NS et al., 2011, Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors., Pharmacogenet Genomics

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name topiramate controlled release,Trokesa

Novel drug target Established target

Trial Name topiramate tablet,Topamax

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Glutamate receptor ionotropic kainate antagonist

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Glutamate receptor ionotropic AMPA antagonist

Direct Interaction yes

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Glutamate receptor ionotropic kainate antagonist

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Glutamate receptor ionotropic AMPA antagonist

Direct Interaction yes

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Glutamate receptor ionotropic kainate antagonist

Direct Interaction yes

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Glutamate receptor ionotropic AMPA antagonist

Direct Interaction yes

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Glutamate receptor ionotropic AMPA antagonist

Direct Interaction yes

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

Trial Name topiramate controlled release,Trokesa

Interaction Types & Directionality:

agonist (activating)

positive modulator (activating)

Interaction Info:

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Direct Interaction yes

Trial Name topiramate controlled release,Trokesa

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name topiramate controlled release,Trokesa

Novel drug target Established target

Trial Name topiramate tablet,Topamax

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Publications:

Dodgson et al., 2000, Topiramate as an inhibitor of carbonic anhydrase isoenzymes., Epilepsia

Nishimori I et al., 2007, Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides., Bioorg Med Chem

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Types & Directionality:

antagonist (inhibitory)

Publications:

Mula M et al., 2006, Psychopharmacology of topiramate: from epilepsy to bipolar disorder., Neuropsychiatr Dis Treat

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Direct Interaction yes

Interaction Types & Directionality:

n/a

Interaction Info:

Direct Interaction yes

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Direct Interaction yes

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Direct Interaction yes

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Direct Interaction yes

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Direct Interaction yes

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Direct Interaction yes

Interaction Types & Directionality:

n/a

Interaction Info:

Direct Interaction yes

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Interaction Types & Directionality:

n/a

Interaction Info:

Mechanism of Interaction GABA-A receptor; anion channel positive modulator

Direct Interaction yes